Safety, PK and PD of FLQ-101 in Premature Neonates
Recruiting
Phase 1
Interventional Study
Retinopathy of Prematurity (ROP)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 4 Days – 5 Days
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 18 (estimated)
- Sponsor
- FELIQS INC. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Written consent is obtained from parent(s) or legal guardian.
* Neonates born at 26 weeks +0 days and 27 weeks +6 days of gestation.
* Male or female infants with a birth weight greater than or equal to 650 gm.
Exclusion Criteria:
* Neonates with congenital malformation of t…
Contacts